IXHL
Incannex Healthcare Inc
$
0.463
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.571
Open
0.3946
VWAP
0.46
Vol
287.34M
Mkt Cap
13.61M
Low
0.3613
Amount
132.48M
EV/EBITDA(TTM)
--
Total Shares
15.87M
EV
4.84M
EV/OCF(TTM)
--
P/S(TTM)
--
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Show More
Valuation Metrics
The current forward P/E ratio for Incannex Healthcare Inc (IXHL.O) is -0.28, compared to its 5-year average forward P/E of -230.22. For a more detailed relative valuation and DCF analysis to assess Incannex Healthcare Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-230.22
Current PE
-0.28
Overvalued PE
201.33
Undervalued PE
-661.76
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.27
Current EV/EBITDA
-1.18
Overvalued EV/EBITDA
0.21
Undervalued EV/EBITDA
-0.76
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
26932.84
Current PS
51.65
Overvalued PS
63771.77
Undervalued PS
-9906.08
Financials
Annual
Quarterly
FY2025Q3
N/A
Total Revenue
FY2025Q3
YoY :
-32.53%
-5.00M
Operating Profit
FY2025Q3
YoY :
-34.21%
-3.97M
Net Income after Tax
FY2025Q3
YoY :
-47.37%
-0.20
EPS - Diluted
FY2025Q3
YoY :
-27.40%
-3.16M
Free Cash Flow
FY2025Q3
100.00
Gross Profit Margin - %
FY2025Q3
N/A
FCF Margin - %
FY2025Q3
-17.77K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IXHL News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
08:17:15
Incannex has no plans, requirement to fully utilized ATM in near term
2025-07-30 (ET)
2025-07-30
08:12:00
Incannex reports results from RePOSA Phase 2 trial of IHL-42X
2025-07-25 (ET)
2025-07-25
07:31:52
Incannex appoints Charlene Gamaldo to clinical advisory board
Sign Up For More Events
Sign Up For More Events
News
4.5
08-01BenzingaEXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
9.5
08-01BenzingaWhy Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
9.5
07-31BenzingaWhy Meta Platforms Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
XBP
XBP Global Holdings Inc
0.619
USD
+4.57%
RENT
Rent the Runway Inc
4.430
USD
+0.23%
VVOS
Vivos Therapeutics Inc
4.520
USD
-2.38%
CXAI
CXApp Inc
0.892
USD
-2.30%
LEXX
Lexaria Bioscience Corp
0.830
USD
-1.07%
CLPS
CLPS Inc
0.905
USD
-0.55%
GORO
Gold Resource Corp
0.496
USD
-3.12%
TZUP
Thumzup Media Corp
15.370
USD
+13.94%
GROW
US Global Investors Inc
2.370
USD
+1.28%
FAQ
What is Incannex Healthcare Inc (IXHL) stock price today?
The current price of IXHL is 0.4625 USD — it has increased 34.2 % in the last trading day.
What is Incannex Healthcare Inc (IXHL)'s business?
What is the price predicton of IXHL Stock?
What is Incannex Healthcare Inc (IXHL)'s revenue for the last quarter?
What is Incannex Healthcare Inc (IXHL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Incannex Healthcare Inc (IXHL)'s fundamentals?
How many employees does Incannex Healthcare Inc (IXHL). have?